Computer system validation is documented evidence that a computerised system does what it is specified to do, consistently, and that the records it produces can be trusted. That is the whole of it. Everything else — the templates, the protocol numbering, the signature pages, the traceability matrix — exists to make that evidence findable and defensible two years later when someone who was not in the room asks how you know.
The obligation is old and stable. What has changed is the effort model. GAMP 5 Second Edition and the FDA's Computer Software Assurance guidance both push teams to spend effort in proportion to patient risk rather than in proportion to page count, and most organisations have not yet rebuilt their practice around that. This guide covers what CSV requires, what the deliverable set actually looks like, who owns which piece, and where packages fail in front of an inspector.
What CSV is, and the failure it exists to prevent
CSV exists because regulated decisions are made on computer-held records. A batch is released because a LIMS result says the assay passed. A subject is enrolled because an EDC system says they met eligibility. A deviation is closed because a QMS workflow says the CAPA was effective. If the system that produced that record was wrong — miscalculated, silently dropped a value, applied the wrong specification version, let an unauthorised user change a result — the decision was wrong, and nobody would know.
So the regulator's question is never "did you validate it?" The question is "show me why I should believe this record." Validation is the answer, written down in advance and evidenced afterwards. This framing matters practically: it tells you where to spend effort. A field that feeds a release decision deserves rigorous testing. A cosmetic dashboard preference does not, and testing it to the same depth is not conservatism — it is effort spent where it buys nothing.
CSV applies across pharmaceuticals, biotechnology, medical devices manufacturers, CROs and diagnostics laboratories. The regulations differ in citation; the underlying expectation does not.
What regulators actually require
Three instruments carry most of the weight, and it is worth being precise about what each one says rather than treating them as a single blur of compliance.
- 21 CFR Part 11 governs electronic records and electronic signatures in FDA-regulated environments. It requires validation of systems to ensure accuracy, reliability and consistent intended performance; secure, computer-generated, time-stamped audit trails; the ability to generate accurate and complete copies in human-readable and electronic form; and signature components bound to their records. Part 11 does not tell you how to validate — it tells you what the record must be able to prove. See 21 CFR Part 11 for the control-by-control breakdown, and our complete Part 11 guide for the detail.
- EU GMP Annex 11 is the European counterpart and is, in places, more explicit about supplier management, risk management, and the lifecycle. It expects a documented risk assessment driving the extent of validation, a current inventory of GMP-relevant systems, and formal agreements with suppliers and service providers. Annex 22 now sits alongside it covering artificial intelligence and machine learning in GMP contexts.
- GAMP 5 Second Edition is not law. It is the industry guidance that regulators recognise as a reasonable interpretation, and its second edition explicitly embraces critical thinking, iterative and Agile delivery, supplier leverage, and software tooling — including automated testing — as legitimate parts of a validated approach. If your SOPs still describe a strictly linear, document-heavy waterfall as the only compliant route, they are implementing the first edition. What changed in GAMP 5 Second Edition covers the deltas.
Two things follow. First, none of these documents mandates a fixed page count or a fixed number of test scripts. Second, all of them expect you to be able to explain why you did what you did. A risk assessment that concludes "test everything equally" has not done its job.
The computer system validation lifecycle, stage by stage
The lifecycle below is the conventional sequence. In practice the stages overlap and iterate, especially on configured systems delivered in sprints, and GAMP 5 Second Edition is comfortable with that. What cannot iterate away is the dependency: you cannot write a meaningful test before you have a stated requirement, and you cannot claim coverage without traceability.
- Validation plan. Scope, system boundary, regulatory basis, GAMP category, roles, deliverable list, acceptance criteria for the package as a whole, and the change-control approach. The boundary statement is the part teams under-write and inspectors probe — say explicitly which interfaces, environments and infrastructure are in scope.
- User Requirements Specification (URS). What the business needs the system to do, in testable language, with each requirement classified for GxP impact. A requirement that cannot be tested is not a requirement; it is a wish. This is the single highest-leverage document in the package, because everything downstream inherits its quality.
- Functional and design specifications (FS/DS). How the system meets the requirements. For a Category 4 configured product, the supplier's documentation plus a configuration specification usually suffices. For Category 5 custom code you need design detail, code review evidence, and unit test records.
- Risk assessment. Functional risk assessment against the URS: what happens if this function fails, how likely is that, how detectable is it. The output drives test depth per requirement — this is where the effort model is actually set. Do it before test authoring or it becomes retrospective justification.
- IQ / OQ / PQ. Installation qualification confirms the system is installed as specified in the target environment (versions, dependencies, configuration, infrastructure). Operational qualification demonstrates each in-scope function behaves as specified, including negative and boundary cases. Performance qualification demonstrates the system supports the actual business process with real users, real data volumes and real workflows.
- Traceability matrix. Requirement to specification to risk to test to result. It must be complete in both directions: every GxP requirement has test coverage, and every test traces to a requirement. Orphan tests are noise; uncovered requirements are findings.
- Validation Summary Report. What was executed, what deviated, how each deviation was dispositioned, what residual risk remains, and the explicit release statement. Unresolved deviations must be closed or formally accepted with rationale before release — never left open and unexplained.
- Periodic review. On a defined interval, confirm the system is still in its validated state: change history, deviation and incident history, user access review, supplier status, audit trail review practice, and whether the original risk assessment still holds.
GAMP categories and what each implies for effort
Category assignment is the main lever on effort, which is exactly why it gets argued about. GAMP 5 recognises four categories in practice (Category 2 was retired).
- Category 1 — infrastructure software. Operating systems, database engines, middleware, virtualisation layers. Not validated as applications; qualified as infrastructure and recorded in IQ. Version control and change management, not test scripts.
- Category 3 — non-configured products. Used as supplied, default configuration only. Validation focuses on the operational process and fitness for intended use — verify it does what you need in your environment, leaning on supplier testing for the product itself. A small instrument data-capture utility used out of the box is the archetype.
- Category 4 — configured products. LIMS, QMS, MES, ERP quality modules, EDC. The software is commercial; the risk lives in your configuration — workflows, roles, specifications, calculations, interfaces. Testing concentrates on configured functions and the interfaces between systems, not on re-proving the vendor's core product. This is the bulk of most portfolios.
- Category 5 — custom applications and custom code. Bespoke applications, custom modules, customised code inside a Category 4 product. Full lifecycle rigour: design specification, code review, unit testing, source control evidence, and the most demanding supplier or development assessment. A single custom calculation inside an otherwise Category 4 LIMS pulls that calculation into Category 5 treatment even if the rest stays at 4.
The category is a starting point for effort, not a verdict. A Category 3 system with a direct feed into batch release may warrant more testing than a Category 4 system used for internal document tracking. Risk wins over category when the two disagree. GAMP 5 categories explained works through the boundary cases, and GAMP 5 Second Edition consulting covers the assessment itself.
The deliverable set, and who owns what
A complete package for a typical Category 4 system contains: validation plan, URS, configuration specification, functional risk assessment, supplier assessment, IQ protocol and executed record, OQ protocol and executed record, PQ protocol and executed record, traceability matrix, deviation records with dispositions, training records for the executors, and the validation summary report. Data migration adds a migration plan and verification report. Part 11 scope adds an assessment of audit trail, access control, and signature controls.
Ownership tends to blur, and blurred ownership is how packages stall.
- System owner / business process owner. Owns the URS and the PQ. They are the ones who know whether the system supports the real process, and they are accountable for the system in operation.
- Validation lead. Owns the plan, the risk assessment, protocol authorship, execution coordination, deviation management, traceability and the summary report. In most organisations this is also the person who carries the practice's institutional memory of what inspectors asked last time.
- Quality Assurance. Approves the plan, the risk assessment and the summary report; reviews deviations; owns the decision that residual risk is acceptable. QA approves — QA does not author the package it approves. Where the same person drafts and approves, you have an independence problem an inspector will name.
- IT / infrastructure. Owns IQ evidence, environment control, backup and restore, and the qualified state of the platform underneath.
- Supplier. Provides product documentation, development and test evidence, and — where you have assessed and qualified them — testing you can legitimately leverage instead of repeating. That leverage is only defensible if a documented supplier assessment supports it. See supplier qualification.
Why CSV packages fail inspection
Packages rarely fail because a test was executed badly. They fail because the story does not hold together when someone pulls on a thread. The recurring patterns:
- Traceability that does not reconcile. Requirements in the URS with no corresponding test, tests referencing requirement IDs that were renumbered mid-project, or a matrix that was built once at the start and never updated through three change controls. This is the most common finding and the easiest to prevent — see why a live RTM beats a static one.
- Deviations closed without real disposition. A test failure annotated "retested OK" with no analysis of why it failed, whether the failure indicated a defect, and whether other tests were affected by the same root cause.
- Risk assessment written after the tests. Detectable from the document dates and from the suspicious way every risk conclusion happens to match the testing that was already planned. Once an inspector sees that, they discount the risk rationale entirely and hold you to a full-coverage standard.
- Unspecified system boundary. The package validates the application but is silent on the interface that feeds it, the reporting layer that reads from it, or the cloud infrastructure it runs on. cloud & SaaS validation is where this surfaces most often now.
- Audit trail present but never reviewed. The system has an audit trail, Part 11 is ticked, and nobody can produce evidence that anyone has ever reviewed it. The control was implemented and not operated.
- Data integrity gaps at the edges. Manual transcription steps, spreadsheets in the middle of an otherwise validated flow, shared logins on an instrument PC. ALCOA+ in practice covers the pattern, and our inspection readiness guide covers how to find these before someone else does.
- Stale validated state. The package was excellent in 2024. Since then the system has had eleven configuration changes and two vendor upgrades, and none of them touched the validation documentation.
How CSA changes the effort model without changing the obligation
Computer Software Assurance is frequently described as a replacement for CSV. It is not. The obligation to have documented evidence that the system is fit for its intended use is unchanged. What CSA changes is where you are expected to spend the effort: critical thinking and risk-based assurance first, documentation as the by-product rather than the objective.
Concretely, CSA sanctions a graded set of assurance activities — unscripted and exploratory testing, ad-hoc testing, robust scripted testing — matched to risk, and it sanctions leveraging supplier activity and automated tooling instead of hand-transcribing screenshots into a Word protocol. For a low-risk, non-direct-impact function, a recorded unscripted test with a clear objective and a captured result can be sufficient evidence. For a function that determines product disposition, you still write the scripted protocol.
The trap is treating CSA as permission to document less without thinking more. Teams that reduce documentation but skip the risk reasoning end up with thinner packages and no rationale for the thinness, which is a worse position than where they started. The teams that get real relief from CSA are the ones who do the risk work properly and can point to it. CSV vs CSA: what actually changed covers the transition, and CSA services covers implementing it against your existing SOPs.
The practical consequence for a 2026 validation practice is that the bottleneck moves. When you are no longer padding protocols, the remaining cost is authoring requirements and tests that are actually good, and keeping traceability current across change. That is the work GxP Copilot drafts — requirements, risk assessments, test scripts and a traceability matrix that updates itself as the system changes — with a qualified reviewer approving every gate before anything is signed. The judgment stays with your people; the mechanical reconstruction does not.
If you are building or rebuilding a practice, the complete GxP validation checklist is the working companion to this guide, our GxP software overview covers the platform landscape, the GxP AI hub covers where AI fits across these stages, and CSV validation services covers doing it with help.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.